• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CARDIOVASCULAR SYSTEMS CORPORATION CAPIOX FX ADVANCE HOLLOW FIBER OXYGENATOR W INTEGRATED AF W HARDSHELL RES.; OXYGENATOR, CARDIOPULMONARY BYPASS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CARDIOVASCULAR SYSTEMS CORPORATION CAPIOX FX ADVANCE HOLLOW FIBER OXYGENATOR W INTEGRATED AF W HARDSHELL RES.; OXYGENATOR, CARDIOPULMONARY BYPASS Back to Search Results
Model Number 3CX*FX25RWC
Medical Device Problem Code Air/Gas in Device (4062)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 02/25/2025
Type of Reportable Event Malfunction
Additional Manufacturer Narrative
Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.For this reason, terumo references evaluation conclusion code 11.
 
Event or Problem Description
The user facility reported to terumo cardiovascular that prior to cardiopulmonary bypass, during prime, a rise of air bubble in venous reservoir.As per user facility, when recirculating the priming volume during preparation, they noticed a significant rise of air bubbles in the venous reservoir, just before the outlet to the arterial pump.When the arterial pump was stopped, a considerable amount of air bubbles rose towards the venous inlet.All 3-way stopcocks in the venous access was replaced to rule out the error.No patient involvement, product was changed out, procedure completed successfully.
 
Additional Manufacturer Narrative
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on march 28, 2025.Upon further investigation of the reported event, the following information is new and/or changed: d9 (device availability - added date returned to manufacturer).G3 (date received by manufacturer).G6 (indication that this is a follow-up report).H2 (follow-up due to additional information).H3 (evaluation is in progress, but not yet concluded).A second follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code 11.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
 
Additional Manufacturer Narrative
This follow-up report is submitted to fda in accord with applicable regulations.Upon further investigation of the reported event, the following information is new and/or changed: b3 (added date of event).G3 (date received by manufacturer).G6 (indication that this is a follow-up report).H2 (follow-up due to additional information and device evaluation).H3 (device evaluated by manufacturer).H6 (identification of evaluation codes 10, 11, 3331, 706, 25).The returned sample was visually inspected, with no anomalies noted.The unit was then set up in a circuit, where in a saline solution was run at 2.5 l/minute for approximately 20 minutes, and then the roller pump was turned up to 6 l/minute for an approximately 1 minute.Air bubbles were noted during the test.The returned sample was then visually inspected after the circuit test, and it was found that the small o-ring on the venous port was not seated properly, allowing air to enter.A representative retention sample was obtained and inspected showing the o-ring seated correctly within the venous port.A partially seated o-ring could cause air to be introduced.The o-ring creates an air-tight seal to prevent air from being drawn into the reservoir during circulation.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CAPIOX FX ADVANCE HOLLOW FIBER OXYGENATOR W INTEGRATED AF W HARDSHELL RES.
Common Device Name
OXYGENATOR, CARDIOPULMONARY BYPASS
Manufacturer (Section D)
TERUMO CARDIOVASCULAR SYSTEMS CORPORATION
125 blue ball road
elkton MD 21921
Manufacturer (Section G)
SAME
Manufacturer Contact
douglas patton
125 blue ball road
elkton, MD 21921
7346634145
MDR Report Key21720607
Report Number1124841-2025-00029
Device Sequence Number9537100
Product Code DTZ
UDI-Device Identifier00699753450837
UDI-Public(01)00699753450837(17)270630(10)4H15
Combination Product (Y/N)N
Initial Reporter CountryGM
PMA/510(K) Number
K151791
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Other,Foreign,Health Professional,User Facility,Company Representative
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup,Followup
Report Date (Section B) 06/02/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Model Number3CX*FX25RWC
Device Catalogue NumberN/A
Device Lot Number4H15
Was Device Available for Evaluation? Device Returned to Manufacturer
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 03/06/2025
Supplement Date Received by Manufacturer04/04/2025
05/09/2025
Initial Report FDA Received Date03/28/2025
Supplement Report FDA Received Date04/28/2025
06/02/2025
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured07/17/2024
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Patient SexUnknown
-
-